| URN | urn:agi-llid:1387 |
|---|---|
| Total Entities | 0 |
| Connectivity | 1286 |
| Name | Crebbp |
| Description | CREB binding protein |
| Notes | A missense mutation has been identified in codon 1175 of CREBBP in a mild case of Rubinstein-Taybi syndrome. A missense mutation has been identified in codon 1175 of CREBBP in a mild case of Rubinstein-Taybi syndrome. CBP acetylation controls HNF6 protein stability. CBP and p300 function as co-activators of Sox9 for cartilage tissue-specific gene expression and chondrocyte differentiation. CBP enhances tumor necrosis alpha-induced cell death in rheumatoid synoviocytes. CBP has a role in regulating 5-aminolevulinate synthase gene expression via the AP-1 complex in human tumor cells. CBP-induced acetylation of AFX is a novel modification mechanism by which AFX keeps the transcriptional activity mitigating in the nucleus. Direct involvement of CREB-binding protein/p300 in sequence-specific DNA binding of virus-activated interferon regulatory factor-3 holocomplex. E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells. Estrogen receptor-alpha represses human GnRH receptor gene transcription via an indirect mechanism involving Creb-binding protein. GCMa acetylation is mediated by CBP, which stimulates GCMa transcriptional activity through cyclic AMP/protein kinase A signaling. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE regulate Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. HIV Tat is a general inhibitor of histone acetylation by cellular HATs and for the CREB-binding protein (CBP), it induces a substrate selectivity. IL-6-inducible expression of the hAGT promoter is mediated by physical association of the COOH terminus of STAT3 with p300/CBP, the recruitment of which targets histone acetylation and results in chromatin remodeling. In 92 patients, we were able to identify a total of 36 mutations in CBP. By using multiple ligation-dependent probe amplification, we found not only several deletions but also the first reported intragenic duplication in a patient with RSTS. In conclusion, this research supports FSCN1 as a novel marker of NT2 neuronal differentiation and the possible role of CBP in its regulation. Interaction of PIMT with transcriptional coactivators CBP, p300, and PBP differential role in transcriptional regulation. Loss of CREBBP was not statistically significant selection in cancer cells stratified by various criteria for the concordant loss of EP300 and CREBBP. Loss of heterozygosity and internal tandem duplication mutations of the CBP gene are frequent events in human esophageal squamous cell carcinoma. Mutations and deletions of the CBP gene is associated with lung cancer. Novel heterozygous deletion in CREBBP in Rubinstein-Taybi syndrome patient results in the loss of exon 30. Oct-1 potentiates CREB-dependent cyclin D1 transcriptional activity by a phospho-CREB and CREB binding protein-independent mechanism. PHD finger mutations cause a loss of CBP acetyltransferase activity. Recruitment of Daxx following SUMO modification represents a previously undescribed mechanism in modulating CREB-binding protein (CBP) transcriptional potential. Regulatory motifs for CREB-binding protein and Nfe2l2 transcription factors in the upstream enhancer of the mitochondrial uncoupling protein 1 gene. Smad-binding peptide aptamers can be developed to selectively inhibit TGF-beta-induced gene expression. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. Suppression of CBP in human mammary epithelial cells results in loss of reconstituted extracellular matrix-mediated growth control and apoptosis and loss of laminin-5 alpha 3-chain expression. The CBP/p300 acetylase and the CARM1 methyltransferase can positively regulate the expression of estrogen-responsive genes, there is a crosstalk between lysine acetylation and arginine methylation on chromatin. The KID-interacting domain of human coactivator CREB-binding protein (CBP) is the CBP domain that is targeted by HIV-1 Tat during HIV-1 propagation. The PHD type zinc finger is an integral part of the CBP acetyltransferase domain. The fact that Egr-1 promoter/reporter gene transcription is upregulated by a constitutively active CREB mutant indicates that the CRE couples other signaling cascades via CREB to the Egr-1 gene. The interaction between CtBP and CBP is functionally important and leads to impairment of histone H3 acetylation by CBP at specific lysine residues (Lys9, Lys14, and Lys18) in a dose-dependent and NADH-dependent manner. The interaction of fibroblast growth factor receptor-1: wiwth CREb binding protein allows activation of gene transcription and may play a role in cell differentiation. The site of the KID-interacting (KIX) domain of CBP that recognizes c-Jun and mixed lineage leukemia MLL proteins is identified as the same site that binds HIV-1 Tat protein. We aimed to determine the rate of point mutations and other small molecular lesions in true Rubinstein-Taybi syndrome and possible mild variants, by using genomic DNA sequencing of the CREBBP gene. Activation of CREB-binding protein and inhibition of MAPK has a role in cAMP-dependent protein kinase type I regulation of ethanol-induced cAMP response element-mediated gene expression. Activity of ESE-1 is positively and negatively modulated by other interacting proteins including Ku70, Ku86, p300, and CBP. Arginine methylation of CBP is required for IFN-gamma induction of MHC-II. A kinetic analysis shows that CIITA, CARM1, and H3-R17 methylation all precede CBP loading on the MHC-II promoter during IFN-gamma treatment. Arginine methylation represents an important mechanism for modulating CBP co-activator transcriptional activity. Deletion of the CBP bromo- and C/H3 domains eliminates stimulation of nucleosomal histone deacetylase activity in vitro and transcriptional coactivation by EBV Zta in transfected cells. Effect of CREB-binding protein on inhibition of Smad-mediated transcriptional activation by K-bZIP was examined. Glutamine rich and bZIP domains stabilize CREB binding to chromatin. Important functions in coordinated cell cycle progression. In human mammary epithelial cells, CBP/p300 were both modulated by an all-trans-retinoic acid (ATRA) signaling pathway and were required for a normal response to ATRA. Interaction of CREB-binding protein with EWS selectively activates hepatocyte nuclear factor 4-mediated transcription. Is co-expressed with CREB and CBP in extravillous cytotrophoblasts, revealing the in vivo relevance of this transactivation pathway. Overexpression of CBP is detected from the very early stages of laryngeal carcinogenesis, suggesting that CBP may play a role in malignant transformation of precancerous laryngeal lesions. P34SEI-1 strongly suppressed CREB-mediated transcription, and this suppression was overcome by excess amount of CBP. Recruitment to pp90RSK regulates cAMP response element-binding protein activity which is negatively affected by ERK phosphorylation. Results suggest that all-trans-retinoic acid and retinoic acid receptors regulate growth arrest of human mammary epithelial cells and modulate CBP/p300 protein expression. Role in acetylation of beta-catenin. Role in transcriptional control of the inflammatory response. Structurally distinct modes of recognition of the KIX domain of this protein by Jun and CREB. Substrate specificity; structure activity relationship. The conserved bromo-domain of the transcriptional coactivator CBP (CREB binding protein) binds specifically to p53 at the C-terminal acetylated lysine 382. The histone chaperone SET regulates CBP-mediated transcription. |
| GO Molecular Function | histone acetyltransferase activity |
|---|---|
| signal transducer activity | |
| RNA polymerase II transcription coactivator activity | |
| RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription | |
| RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription | |
| transcription cofactor activity | |
| transcription coactivator activity | |
| sequence-specific DNA binding transcription factor activity | |
| transferase activity | |
| acetyltransferase activity | |
| chromatin binding | |
| SMAD binding | |
| transcription factor binding | |
| p53 binding | |
| RNA polymerase II transcription factor binding | |
| activating transcription factor binding | |
| RNA polymerase II activating transcription factor binding | |
| MRF binding | |
| peroxisome proliferator activated receptor binding | |
| DNA binding | |
| core promoter proximal region sequence-specific DNA binding | |
| metal ion binding | |
| zinc ion binding |
| GO Cellular Component | nucleoplasm |
|---|---|
| histone acetyltransferase complex | |
| nuclear body | |
| PML body | |
| nuclear chromatin | |
| condensed chromosome outer kinetochore | |
| protein complex | |
| transcription factor complex | |
| cytoplasm | |
| nucleus |
| GO Biological Process | innate immune response |
|---|---|
| cell proliferation | |
| small molecule metabolic process | |
| histone acetylation | |
| cellular lipid metabolic process | |
| positive regulation of type I interferon production | |
| embryonic digit morphogenesis | |
| germ-line stem cell maintenance | |
| positive regulation of G1-S transition of mitotic cell cycle | |
| signal transduction | |
| regulation of smoothened signaling pathway | |
| Notch signaling pathway | |
| cellular response to hypoxia | |
| regulation of transcription from RNA polymerase II promoter in response to hypoxia | |
| response to hypoxia | |
| positive regulation of transcription, DNA-templated | |
| positive regulation of transcription from RNA polymerase II promoter | |
| negative regulation of transcription from RNA polymerase II promoter | |
| regulation of transcription, DNA-templated | |
| positive regulation of sequence-specific DNA binding transcription factor activity | |
| transcription, DNA-templated | |
| transcription from RNA polymerase II promoter | |
| transcription initiation from RNA polymerase II promoter | |
| N-terminal peptidyl-lysine acetylation | |
| gene expression | |
| modulation by virus of host morphology or physiology | |
| protein complex assembly | |
| homeostatic process |
| Pathway | SRCAP Chromatin Remodeling |
|---|---|
| Histone Acetylation | |
| Androgen Receptor to Akt Signaling in Prostate Cancer | |
| Contraction-Induced IL6 Up-regulation in Skeletal Muscles | |
| FLT3 and KIT Signaling to MLL Pathway in Acute Myeloid Leukemia (M5) | |
| Acute Myeloid Leukemia Overview | |
| Proteins Involved in Pathogenesis of Acute Myeloid Leukemia | |
| B-cell Acute Lymphoblastic Leukemia Overview | |
| Diffuse Large-B-cell Lymphoma, GCB Subtype | |
| Diffuse Large-B-cell Lymphoma Overview | |
| Follicular Lymphoma Overview | |
| Hereditary Breast and Ovarian Cancer Syndrome | |
| Breast Cancer Related to ESR1 Signaling Pathway | |
| Breast Cancer Related to NOTCH1 Signaling Pathway | |
| Proteins Involved in Pathogenesis of Breast Cancer Related to ESR1 Signaling Pathway | |
| ESR1/ERBB-positive Luminal Breast Cancer | |
| Basal Breast Cancer | |
| Proliferative Diabetic Retinopathy | |
| Clear Cell Ovarian Carcinoma | |
| Mucinous Ovarian Carcinoma | |
| High-grade Serous Ovarian Carcinoma | |
| Endometrioid Ovarian Carcinoma | |
| Ovarian Cancer Overview | |
| Low-grade Serous Ovarian Carcinoma | |
| Type I Endometrial Cancer (Endometrioid Endometrial Cancer) | |
| Type II Endometrial Cancer (Clear-cell Endometrial Cancer and Papillary Serous Endometrial Cancer) | |
| Endometrial Cancer Overview | |
| MITF as a Regulator of Melanoma Cell Development | |
| Melanoma Overview | |
| Cancer Overview | |
| CFTR Up-regulates the Oxidative Stress in Airway Epithelium in Cystic Fibrosis | |
| Steroid-Induced Cataract | |
| Pancreatic Ductal Carcinoma | |
| NOTCH Signaling in Hepatocellular Carcinoma | |
| Hepatocellular Carcinoma Overview | |
| Proteins Involved in Pathogenesis of Amyotrophic Lateral Sclerosis | |
| Induction of Apoptosis and Immediate Early Gene Activation in Hippocampal Neurons Following Seizures | |
| HRH2/4 -> IL6/10 production | |
| Summarized nociception-related expression targets | |
| FGFR -> AP-1/CREB/CREBBP/ELK-SRF/MYC signaling | |
| T-cell receptor -> CREBBP signaling | |
| FLT3LG/AP-1/CREB/CREBBP Expression Targets | |
| PGF/AP-1/CREB/CREBBP/MYC Expression Targets | |
| Thrombopoietin/AP-1/CREB/CREBBP/MYC Expression Targets | |
| AREG/CREB/CREBBP Expression Targets | |
| NRG1/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| TGFA/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| FGF7/AP-1/CREB/CREBBP/MYC Expression Targets | |
| FGF10/AP-1/CREB/CREBBP/MYC Expression Targets | |
| CSF1/AP-1/CREB/CREBBP/MYC Expression Targets | |
| ANGPT1/CREB/CREBBP Expression Targets | |
| ANGPT2/AP-1/CREBBP/MYC Expression Targets | |
| IL16/ATF/CREB/CREBBP Expression Target | |
| CD8/ATF/CREB/CREBBP Expression Targets | |
| CD80/ATF/CREB/CREBBP Expression Targets | |
| CD86/ATF/CREB/CREBBP Expression Targets | |
| CD72/CREB/CREBBP Expression Targets | |
| PDCD1/ATF/CREB/CREBBP Expression Targets | |
| TCR/CREB/CREBBP/ATF Expression Targets | |
| FGF2/AP-1/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| KITLG/AP-1/CREB/CREBBP/MYC Expression Targets | |
| PDGF/AP-1/CREB/CREBBP/MYC Expression Targets | |
| VEGFA/AP-1/CREBBP/MYC Expression Targets | |
| RNA polymerase I transcription pathway | |
| Wnt signaling, canonical pathway | |
| Wnt signaling, canonical pathway | |
| altered Wnt signaling, canonical pathway | |
| RNA polymerase I transcription pathway | |
| canonical Wnt signaling pathway | |
| altered canonical Wnt signaling pathway | |
| canonical Wnt signaling pathway | |
| altered canonical Wnt signaling pathway | |
| Huntington disease pathway | |
| nuclear factor, erythroid 2 like 2 signaling pathway |
| Group | Transcription factors |
|---|---|
| innate immune response | |
| cell proliferation | |
| small molecule metabolic process | |
| histone acetylation | |
| histone acetyltransferase activity | |
| cellular lipid metabolic process | |
| positive regulation of type I interferon production | |
| embryonic digit morphogenesis | |
| germ-line stem cell maintenance | |
| positive regulation of G1-S transition of mitotic cell cycle | |
| signal transduction | |
| signal transducer activity | |
| regulation of smoothened signaling pathway | |
| Notch signaling pathway | |
| cellular response to hypoxia | |
| regulation of transcription from RNA polymerase II promoter in response to hypoxia | |
| response to hypoxia | |
| positive regulation of transcription, DNA-templated | |
| positive regulation of transcription from RNA polymerase II promoter | |
| RNA polymerase II transcription coactivator activity | |
| negative regulation of transcription from RNA polymerase II promoter | |
| RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription | |
| RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription | |
| regulation of transcription, DNA-templated | |
| transcription cofactor activity | |
| transcription coactivator activity | |
| sequence-specific DNA binding transcription factor activity | |
| positive regulation of sequence-specific DNA binding transcription factor activity | |
| transferase activity | |
| acetyltransferase activity | |
| transcription, DNA-templated | |
| transcription from RNA polymerase II promoter | |
| transcription initiation from RNA polymerase II promoter | |
| N-terminal peptidyl-lysine acetylation | |
| gene expression | |
| modulation by virus of host morphology or physiology | |
| protein complex assembly | |
| homeostatic process | |
| chromatin binding | |
| SMAD binding | |
| transcription factor binding | |
| p53 binding | |
| RNA polymerase II transcription factor binding | |
| activating transcription factor binding | |
| RNA polymerase II activating transcription factor binding | |
| MRF binding | |
| peroxisome proliferator activated receptor binding | |
| DNA binding | |
| core promoter proximal region sequence-specific DNA binding | |
| metal ion binding | |
| zinc ion binding | |
| nucleoplasm | |
| histone acetyltransferase complex | |
| nuclear body | |
| PML body | |
| nuclear chromatin | |
| condensed chromosome outer kinetochore | |
| protein complex | |
| transcription factor complex | |
| cytoplasm | |
| nucleus | |
| Genes with Mutations Associated with B-cell Acute Lymphoblastic Luekemia | |
| Proteins Involved in Pathogenesis of B-cell Acute Lymphoblastic Leukemia | |
| Genes with Mutations Associated with Diffuse Large-B-cell Lymphoma, GCB Subtype | |
| Genes with Mutations Associated with Follicular Lymphoma | |
| Proteins Involved in Pathogenesis of Hereditary Breast and Ovarian Cancer Syndrome | |
| Biofluids assayable substances |
| LocusLink ID | 1387 |
|---|---|
| 12914 | |
| 54244 | |
| 436331 |
| Cell Localization | Nucleus |
|---|---|
| Cytoplasm |
| GO ID | 0043426 |
|---|---|
| 0001102 | |
| 0001078 | |
| 0001105 | |
| 0001085 | |
| 0001191 | |
| 0016407 | |
| 0003682 | |
| 0000987 | |
| 0004402 | |
| 0002039 | |
| 0003700 | |
| 0004871 | |
| 0003713 | |
| 0008134 | |
| 0008270 | |
| 0018076 | |
| 0007219 | |
| 0044255 | |
| 0071456 | |
| 0042733 | |
| 0010467 | |
| 0030718 | |
| 0016573 | |
| 0042592 | |
| 0045087 | |
| 0019048 | |
| 0000122 | |
| 0045893 | |
| 0032481 | |
| 0006461 | |
| 0008589 | |
| 0061418 | |
| 0006355 | |
| 0001666 | |
| 0007165 | |
| 0044281 | |
| 0006367 | |
| 0000940 | |
| 0005737 | |
| 0000123 | |
| 0016604 | |
| 0000790 | |
| 0005654 | |
| 0005634 | |
| 0005667 | |
| 0003677 | |
| 0046332 | |
| 0033613 | |
| 0046872 | |
| 0042975 | |
| 0003712 | |
| 0016740 | |
| 0008283 | |
| 1900087 | |
| 0051091 | |
| 0045944 | |
| 0006366 | |
| 0006351 | |
| 0016605 | |
| 0043234 | |
| 0033554 | |
| 0033261 | |
| 0051577 | |
| 0044419 | |
| 0045941 | |
| 0045449 | |
| 0016563 | |
| 0006350 | |
| 0005515 |
| Alias | CBP |
|---|---|
| RSTS | |
| KAT3A | |
| CREB-binding protein | |
| AW558298 | |
| CBP/p300 | |
| p300/CBP | |
| RTS | |
| histone acetyltransferase CBP | |
| cyclic AMP-response element-binding protein-binding protein | |
| cyclic AMP-response element binding protein binding protein | |
| cyclic AMP responsive element-binding protein-binding protein | |
| cyclic AMP-response element-binding protein binding protein | |
| LOC436331 | |
| LOC497663 | |
| LOC547230 | |
| CREB protein binding protein | |
| Rubinstein-Taybi syndrome protein | |
| cyclic AMP responsive element-binding protein binding protein | |
| CBP_MOUSE | |
| Rubinstein-Taybi syndrome gene | |
| cAMP response element-binding protein-binding protein | |
| cAMP response element-binding protein binding protein | |
| cyclic AMP responsive element binding protein binding protein | |
| cAMP responsive element binding protein binding protein | |
| cAMP responsive element-binding protein binding protein | |
| cAMP responsive element-binding protein-binding protein | |
| cAMP-response element-binding protein binding protein | |
| cAMP-response element-binding protein-binding protein | |
| CREB binding protein | |
| CREBBP | |
| cyclic AMP response element binding protein binding protein | |
| cyclic AMP response element-binding protein binding protein | |
| cyclic AMP response element-binding protein-binding protein | |
| cAMP-response element binding protein binding protein | |
| cAMP response element binding protein binding protein | |
| Creb binding protein (CBP) | |
| similar to CREB-binding protein |
| Mouse chromosome position | 16 2.4 cM |
|---|---|
| 16 A1 |
| OMIM ID | 600140 |
|---|---|
| 180849 |
| Rat chromosome position | 10q12 |
|---|
| Hugo ID | 2348 |
|---|
| Human chromosome position | 16p13.3 |
|---|
| Swiss-Prot Accession | Q92793 |
|---|---|
| F8VPR5 | |
| Q6GQV9 | |
| P45481 | |
| F1M9G7 | |
| Q6JHU9 | |
| D3DUC9 | |
| O00147 | |
| Q16376 | |
| Q4LE28 | |
| O60424 | |
| Q4G0V0 | |
| Q712H6 | |
| Q75MY6 | |
| Q3V351 | |
| Q8QZV8 | |
| Q812C1 | |
| Q812C2 | |
| Q91XT1 |
| PIR ID | S39162 |
|---|
| Unigene ID | Hs.459759 |
|---|---|
| Mm.132238 | |
| Mm.392384 | |
| Rn.12815 | |
| Rn.108128 | |
| Mm.387139 | |
| Mm.392739 | |
| Mm.386759 | |
| Mm.393135 |
| KEGG ID | hsa:1387 |
|---|---|
| mmu:12914 | |
| rno:54244 |
| Swiss-Prot ID | CBP_HUMAN |
|---|---|
| Q4LE28_HUMAN | |
| D3DUC9_HUMAN | |
| Q6GQV9_MOUSE | |
| Q6JHU9_RAT |
| EC Number | 2.3.1.48 |
|---|
| Ensembl ID | ENSG00000005339 |
|---|---|
| ENSP00000262367 | |
| ENST00000262367 | |
| ENSMUSG00000022521 | |
| ENSMUSP00000023165 | |
| ENSMUST00000023165 | |
| ENSRNOG00000005330 | |
| ENSRNOP00000007079 | |
| ENSRNOT00000007079 |
| Homologene ID | 68393 |
|---|
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| MGI ID | 1098280 |
|---|
| RGD ID | 2401 |
|---|
| MedScan ID | 1387 |
|---|
| Primary Cell Localization | Nucleus |
|---|
| IPI ID | IPI00023339 |
|---|---|
| IPI00619932 | |
| IPI00463549 | |
| IPI00155855 | |
| IPI00875480 | |
| IPI00652158 | |
| IPI00751842 | |
| IPI00421436 | |
| IPI00781902 |